Aardvark Therapeutics, Inc. (AARD)

Aardvark Therapeutics' stock has been impacted by several events in the past six months. The company announced a voluntary pause of its Phase 3 HERO trial for ARD-101 in Prader-Willi Syndrome on February 27, 2026. Aardvark Therapeutics reported its fourth quarter and full year 2025 financial results on March 23, 2026, and its first quarter 2026 financial results and business updates on May 7, 2026. As of April 17, 2026, the stock price was $5.23, with a market capitalization of $109 million, and a 52-week range between $3.35 and $17.94.

The demand for Aardvark Therapeutics' products and services is not subject to typical seasonal fluctuations. Demand will primarily be driven by the progression of its clinical trials, regulatory approvals, and the medical need for its therapeutic solutions, rather than seasonal patterns.

Aardvark Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule therapeutics that activate innate homeostatic pathways to treat metabolic diseases, especially those related to hunger. Their research targets Bitter Taste Receptors (TAS2Rs) in the gut to regulate metabolic and inflammatory pathways, with a lead product candidate, ARD-101, in Phase 3 clinical development for hyperphagia associated with Prader-Willi Syndrome (PWS) and hypothalamic obesity. The company is also developing ARD-201, a fixed-dose combination of ARD-101 with a DPP-4 inhibitor, and has other projects like WE-868 in various stages of development.

Aardvark Therapeutics, Inc. is headquartered in San Diego, California, United States.

Information specifically detailing Aardvark Therapeutics' brand reputation is not explicitly available in the provided search results. The company actively participates in scientific and investor conferences, such as ObesityWeek and various healthcare and cardiometabolic forums, where it presents preclinical and clinical data on its pipeline, contributing to its professional standing within the biopharmaceutical community.

Insider ownership transactions occurred in September 2025, with Tien-Li Lee and Nelson Sun purchasing shares, Tien Lee is the Founder and Chief Executive Officer of Aardvark.